011040 — Kyung Dong Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapNeutral

Annual income statement for Kyung Dong Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	177,611	182,718	162,674	193,936	196,273
Cost of Revenue
Gross Profit	97,170	94,994	88,306	113,663	116,475
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	161,855	174,906	187,347	191,430	189,207
Operating Profit	15,755	7,812	-24,673	2,506	7,066
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	18,432	17,941	-18,503	5,221	9,123
Provision for Income Taxes
Net Income After Taxes	12,627	12,113	-20,730	5,448	8,451
Minority Interest
Net Income Before Extraordinary Items
Net Income	12,672	12,161	-20,708	5,470	8,529
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	12,672	12,161	-20,708	5,470	8,540
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	459	463	-771	203	342
Dividends per Share